RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

Core Insights - Recordati has entered into an exclusive licensing and supply agreement with Amarin to commercialize Vazkepa in 59 European countries, which is expected to enhance growth in Specialty & Primary Care segments [1][6] - Vazkepa is indicated for reducing cardiovascular event risks in high-risk patients and has a strong clinical data package supporting its efficacy [2][6] Product and Market Overview - Vazkepa was approved in the EU and UK in 2021 and in Switzerland in 2022, based on the REDUCE-IT study involving over 8,000 patients, demonstrating significant reductions in Major Adverse Cardiovascular Events (MACE) [2] - The product is currently marketed in 11 European countries, generating net sales of €12 million in 2024, with projections of over €40 million in revenues by 2027 and expected to be EBITDA positive from 2026 [3] Financial Terms of the Agreement - Under the agreement, Recordati will make an upfront cash payment of US$25 million to Amarin, with potential royalties and commercial milestones totaling up to US$150 million if annual revenues exceed €100 million [4] Strategic Importance - The agreement is seen as a strategic move to strengthen Recordati's position in the cardiovascular space and enhance its Specialty & Primary Care business with innovative treatments [6] - The patent protection for Vazkepa in Europe extends until 2039, providing a long-term opportunity for growth and impact on patient care [2][6]